Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by fredgoodwinsonon Jun 17, 2022 3:16am
194 Views
Post# 34763543

RE:RE:RE:RE:RE:Not long until the AGM

RE:RE:RE:RE:RE:Not long until the AGM
CancerSlayer wrote:

 

Jaro1977 wrote: If they take questions at the AGM, what would you be asking?

 

 

The most important wish for me is to have the ability to better gauge the durability of response.  I would want to know the "absolute number" of patients who have reached the 270, 360 & 450 day assessment marks, & what number or percentage of those patients are CR.  They could report these numbers for optimized patients only (+/- Ph 1b patients) & for the total patient population, including the underdosed first 12.  That's a start.



Yes CS it`s not just a question for the AGM but price sensitive information seminal to any ability to properly value TLT that being in the Company`s possession and not of commercial sensitivity in relation to their intellectual property should absolutely have been released in a clear and unambiguous format already.


<< Previous
Bullboard Posts
Next >>